Metabolic tumor burden: A new promising way to reach precise personalized therapy in PDAC
Metabolic tumor burden: A new promising way to reach precise personalized therapy in PDAC
复制标题
代谢肿瘤负荷：PDAC 中实现精确个性化治疗的一种新的有前途的方法
DOI：
10.1016/j.canlet.2015.01.023
复制
发表时间：
2015
期刊：
影响因子：
9.7
通讯作者：
Xianjun Yu
中科院分区：
文献类型：
--
作者：
Jinfeng Xiang;Liang Liu;Wenquan Wang;Huaxiang Xu;Chuntao Wu;Jin Xu;Chen Liu;Jiang Long;Quanxing Ni;Xianjun Yu
胰腺癌是目前最致命的实体恶性肿瘤之一，而胰腺导管腺癌（PDAC）是最常见的胰腺癌类型。在过去的十年中，PDAC 的诊断和手术技术一直在稳步发展。然而，PDAC 患者的临床结果几乎没有改善（如果有的话）。基于准确预测胰腺癌患者预后的亚组分类对于治疗选择和临床决策具有重要意义。传统的预后评估方法依赖于TNM分期系统，但由于个体生物学差异，可能无法反映每个患者的真实状态。代谢组学是一个涉及生物系统中存在的代谢物的识别和定量的研究领域。分析癌组织和非癌组织之间的代谢差异可以为与疾病预后和诊断密切相关的肿瘤生物学提供新的见解。因此，代谢肿瘤负荷的评估可以提高临床决策过程的准确性，从而有助于优化胰腺癌的治疗策略。
Pancreatic cancer is currently one of the deadliest solid malignancies and pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. In the past decade, diagnostics and surgical techniques for PDAC have been evolving steadily; however, clinical outcomes of patients with PDAC have shown little, if any, improvement. Subgroup classification based on accurate prediction of prognosis in patients with pancreatic cancer is important for treatment selection and clinical decision-making. The traditional method to evaluate prognosis relies on the TNM staging system, but it may not reflect the true status of every patient due to individual biological differences. Metabolomics is a field of study that involves the identification and quantification of metabolites present in a biological system. Analysis of metabolic differences between cancerous and noncancerous tissues can provide novel insights into tumor biology that are closely associated with disease prognosis and diagnosis. Therefore, evaluation of metabolic tumor burden may improve the accuracy of the clinical decision-making process, thereby facilitating optimization of the treatment strategies for pancreatic cancer.